Micell Technologies is a privately held biomedical company with a concentrated focus on developing an advanced method for vascular drug delivery. This delivery approach is designed to produce better safety outcomes, and could have a significant impact on the field of interventional cardiology.

The Company's patented processes and methods for medical device surface modification using supercritical fluids are focused on resolving known problems with current polymer-based drug-eluting technologies. The company's lead product candidate, MiStent is being developed to merge the therapeutic efficacy potential of a drug-eluting stent with the long-term safety and stability characteristics of a bare-metal stent.